0

    540729

    VANTABIO

    img img img img
    No Data Available

    Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

    Vanta Bioscience Limited Share Price Today

    Investment Returns

    Over 1 Month -1.47% Over 3 Months 44.33% Over 6 Months 28.68% Over 1 Year -8.78%
    demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

    Vanta Bioscience Limited fundamentals


    • Market cap (Cr) [-]
    • P/E Ratio (TTM) [-]
    • Beta [-]
    • Book Value / share [-]
    • Return on equity [-]%
    • EPS (TTM) [-]
    • Dividend yield [-]%
    • Net profit/quarter (Cr) [-]
    info icon alternate text
    • Market cap (Cr) 18.00
    • P/E Ratio (TTM) 148.76
    • Beta 1.70
    • Book Value / share 29.88
    • Return on equity 0.00%
    • EPS (TTM) 0.17
    • Dividend yield [-]%
    • Net profit/quarter (Cr) -1.22
    info icon alternate text

    Vanta Bioscience Limited Financials

    • Key Results
    • Key Ratios
    • Balance sheet
    • Cash Flow
    • Competition
    Open financial information
    Revenue
    Net income
    Particulars MAR 2023 (Values in Cr)
    Revenue 1.76
    Operating Expense 0.00
    Net Profit -1.22
    Net Profit Margin (%) -69.31
    Earnings Per Share (EPS) 0.00
    EBITDA 0.00
    Effective Tax Rate (%) 0.00
    Particulars DEC 2022 (Values in Cr)
    Revenue 1.71
    Operating Expense 3.21
    Net Profit -1.51
    Net Profit Margin (%) -88.30
    Earnings Per Share (EPS) -2.39
    EBITDA 0.32
    Effective Tax Rate (%) -0.67
    Particulars DEC 2021 (Values in Cr)
    Revenue 0.00
    Operating Expense 0.00
    Net Profit 0.00
    Net Profit Margin (%) 0.00
    Earnings Per Share (EPS) 0.00
    EBITDA 0.00
    Effective Tax Rate (%) 0.00
    Particulars MAR 2026 (Values in Cr)
    Revenue 1.82
    Operating Expense 1.95
    Net Profit 0.12
    Net Profit Margin (%) 6.59
    Earnings Per Share (EPS) 0.17
    EBITDA 1.20
    Effective Tax Rate (%) -300.00
    Particulars MAR 2025 (Values in Cr)
    Revenue 1.13
    Operating Expense 3.88
    Net Profit -2.66
    Net Profit Margin (%) -235.39
    Earnings Per Share (EPS) -4.21
    EBITDA -1.62
    Effective Tax Rate (%) 2.20
    Particulars MAR 2024 (Values in Cr)
    Revenue 8.56
    Operating Expense 8.55
    Net Profit 0.05
    Net Profit Margin (%) 0.58
    Earnings Per Share (EPS) 0.08
    EBITDA 3.70
    Effective Tax Rate (%) -25.00
    Particulars MAR 2023 (Values in Cr)
    Revenue 5.17
    Operating Expense 10.01
    Net Profit -4.24
    Net Profit Margin (%) -82.01
    Earnings Per Share (EPS) -6.71
    EBITDA 0.14
    Effective Tax Rate (%) -0.71
    Particulars MAR 2022 (Values in Cr)
    Revenue 9.35
    Operating Expense 9.37
    Net Profit 0.08
    Net Profit Margin (%) 0.85
    Earnings Per Share (EPS) 0.12
    EBITDA 3.57
    Effective Tax Rate (%) 42.85
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share 16.51
    ROE % 0.00
    ROCE % 0.00
    Total Debt to Total Equity 5.11
    EBITDA Margin -211.22
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 24.08
    ROE % 0.00
    ROCE % 0.00
    Total Debt to Total Equity 3.61
    EBITDA Margin 14.61
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share 27.75
    ROE % 0.00
    ROCE % 0.00
    Total Debt to Total Equity 2.46
    EBITDA Margin -27.07
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share 38.03
    ROE % 0.54
    ROCE % 3.99
    Total Debt to Total Equity 1.69
    EBITDA Margin 40.14
    Particulars MAR 2021 (Values in Cr)
    Book Value / Share 37.89
    ROE % 1.90
    ROCE % 5.42
    Total Debt to Total Equity 1.13
    EBITDA Margin 39.64
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share 27.14
    ROE % 0.00
    ROCE % 0.00
    Total Debt to Total Equity 1.51
    EBITDA Margin -143.36
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 31.36
    ROE % 0.05
    ROCE % 5.24
    Total Debt to Total Equity 1.29
    EBITDA Margin 42.76
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share 31.28
    ROE % 0.00
    ROCE % 0.00
    Total Debt to Total Equity 1.06
    EBITDA Margin 2.90
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share 38.01
    ROE % 0.33
    ROCE % 5.24
    Total Debt to Total Equity 0.79
    EBITDA Margin 38.18
    Particulars MAR 2021 (Values in Cr)
    Book Value / Share 37.88
    ROE % 1.99
    ROCE % 6.75
    Total Debt to Total Equity 0.66
    EBITDA Margin 39.04
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 0.22
    Total Assets 85.87
    Total Liabilities 85.87
    Total Equity 3.78
    Share Outstanding 0
    Price to Book Ratio 0.82
    Return on Assets (%) -5.55
    Return on Capital (%) -6.46
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 0.16
    Total Assets 85.39
    Total Liabilities 85.39
    Total Equity 12.97
    Share Outstanding 0
    Price to Book Ratio 2.04
    Return on Assets (%) -2.71
    Return on Capital (%) -3.13
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 0.09
    Total Assets 84.70
    Total Liabilities 84.70
    Total Equity 18.92
    Share Outstanding 0
    Price to Book Ratio 1.84
    Return on Assets (%) -7.65
    Return on Capital (%) -8.52
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 0.22
    Total Assets 81.40
    Total Liabilities 81.40
    Total Equity 29.34
    Share Outstanding 0
    Price to Book Ratio 2.89
    Return on Assets (%) 0.10
    Return on Capital (%) 0.13
    Particulars MAR 2021 (Values in Cr)
    Cash & Short Term Investments 2.65
    Total Assets 69.62
    Total Liabilities 69.62
    Total Equity 26.22
    Share Outstanding 0
    Price to Book Ratio 4.30
    Return on Assets (%) 0.64
    Return on Capital (%) 0.77
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 0.14
    Total Assets 55.83
    Total Liabilities 55.83
    Total Equity 17.13
    Share Outstanding 0
    Price to Book Ratio 0.82
    Return on Assets (%) -4.76
    Return on Capital (%) -5.59
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 0.14
    Total Assets 52.90
    Total Liabilities 52.90
    Total Equity 19.79
    Share Outstanding 0
    Price to Book Ratio 2.04
    Return on Assets (%) 0.09
    Return on Capital (%) 0.11
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 0.06
    Total Assets 51.63
    Total Liabilities 51.63
    Total Equity 19.74
    Share Outstanding 0
    Price to Book Ratio 1.84
    Return on Assets (%) -8.20
    Return on Capital (%) -9.31
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 0.06
    Total Assets 50.39
    Total Liabilities 50.39
    Total Equity 23.98
    Share Outstanding 0
    Price to Book Ratio 2.89
    Return on Assets (%) 0.15
    Return on Capital (%) 0.18
    Particulars MAR 2021 (Values in Cr)
    Cash & Short Term Investments 0.06
    Total Assets 46.24
    Total Liabilities 46.24
    Total Equity 23.91
    Share Outstanding 0
    Price to Book Ratio 4.30
    Return on Assets (%) 1.01
    Return on Capital (%) 1.14
    Particulars MAR 2024 (Values in Cr)
    Net Income -8.82
    Cash from Operations 2.68
    Cash from Investing -3.31
    Cash from Financing 0.69
    Net change in Cash 0.06
    Free Cash Flow 6.08
    Particulars MAR 2023 (Values in Cr)
    Net Income -10.26
    Cash from Operations -0.62
    Cash from Investing -5.90
    Cash from Financing 6.40
    Net change in Cash -0.12
    Free Cash Flow 28.06
    Particulars MAR 2022 (Values in Cr)
    Net Income 0.22
    Cash from Operations 5.27
    Cash from Investing -17.18
    Cash from Financing 9.53
    Net change in Cash -2.42
    Free Cash Flow 5.61
    Particulars MAR 2021 (Values in Cr)
    Net Income 0.58
    Cash from Operations 6.97
    Cash from Investing -22.19
    Cash from Financing 17.78
    Net change in Cash 2.45
    Free Cash Flow 7.82
    Particulars MAR 2020 (Values in Cr)
    Net Income 1.34
    Cash from Operations 2.34
    Cash from Investing -7.35
    Cash from Financing 2.17
    Net change in Cash -3.07
    Free Cash Flow 2.68
    Particulars MAR 2024 (Values in Cr)
    Net Income 0.04
    Cash from Operations 4.54
    Cash from Investing -1.66
    Cash from Financing -2.80
    Net change in Cash 0.07
    Free Cash Flow 4.55
    Particulars MAR 2023 (Values in Cr)
    Net Income -4.20
    Cash from Operations 0.64
    Cash from Investing -2.53
    Cash from Financing 1.88
    Net change in Cash 0.00
    Free Cash Flow 3.17
    Particulars MAR 2022 (Values in Cr)
    Net Income 0.13
    Cash from Operations 6.70
    Cash from Investing -8.05
    Cash from Financing 1.37
    Net change in Cash 0.00
    Free Cash Flow 14.75
    Particulars MAR 2021 (Values in Cr)
    Net Income 0.60
    Cash from Operations 11.00
    Cash from Investing -9.85
    Cash from Financing -1.07
    Net change in Cash -0.02
    Free Cash Flow 11.88
    Particulars MAR 2020 (Values in Cr)
    Net Income 1.28
    Cash from Operations 3.16
    Cash from Investing -1.34
    Cash from Financing -1.80
    Net change in Cash -0.19
    Free Cash Flow 3.51
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    APOLLO HOSPITALS ENTERPRISE LT 8897.35 65.40 13.50 127930.24 6680.00 8917.95
    FORTIS MALAR HOSPITALS LIMITED 52.38 23.70 2.85 98.17 40.75 76.00
    SHREE PACETRONIX LTD. 129.50 15.45 2.72 48.56 71.00 283.15
    TRANSGENE BIOTEK LTD. 2.96 0.00 2.67 22.43 1.83 5.26
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    APOLLO HOSPITALS ENTERPRISE LT 8897.35 85.22 12.84 127930.24 6680.00 8917.95
    [-] 0.0 0.0 0.0 0.0 0.0 0.0
    CHENNAI MEENAKSHI MULTISPECIAL 38.43 0.00 -9.35 28.71 30.30 57.48
    KOVAI MEDICAL CENTER & HO 6041.50 27.04 5.00 6609.40 5010.00 6725.00

    Vanta Bioscience Limited shareholding pattern

    Holding
    27.19%
    72.8%
    Name Shares Category
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)

    Vanta Bioscience Limited Technicals Summary

    • EMA & SMA
    • Resistance and Support
    • Delivery and Volume
    • Beta
    • Price Change Analysis
    25.29 4.98 redarrow
    red-green-graph indicator
    8 Bearish
    8 Bullish
    • 5 Days 24.70
    • 26 Days 22.30
    • 10 Days 24.10
    • 50 Days 21.30
    • 12 Days 23.80
    • 100 Days 21.90
    • 20 Days 22.80
    • 200 Days 26.30
    24.09 PIVOT
    First Support 24.09 First Resistance 24.09 Second Support 24.09 Second Resistance 24.09 Third Support 24.09 Third Resistance 24.09
    RSI 58.89 ADX 18.59 MACD 1.52 Williams % R -45.71 Commodity Channel Index (CCI) 59.60
    Date 2026-06-25 Week 2250.00 Same Day 750.00 Month 1950.00
    1 Year 1.68 3 Year 0.82
    Over 1 Month
    -1.47% down
    Over 1 Year
    -8.78% down
    Over 3 Months
    44.33% down
    Over 3 Years
    -19.47% down
    Over 6 Months
    28.68% down
    Over 5 Years
    -31.52% down

    Vanta Bioscience Limited Corporate Actions

    Top Gainers

    Top Losers

    stock
    Trade stocks with ease

    Sign-in to trade with your demat account, or set up a new demat account for free

    Board Of Directors

    Similar stocks

    Frequently Asked Questions

    What is the Current Share Price of Vanta Bioscience Ltd?

    Answer Field

    Vanta Bioscience Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 25.29 as on Jul 06 2026 12:00 AM.

    What is the Market Cap of Vanta Bioscience Ltd Share?

    Answer Field

    The market cap of Vanta Bioscience Ltd for NSE ₹ 0.00 & for BSE ₹ 18.00 as on Jul 06 2026 12:00 AM.

    What is the 52 Week High and Low of Vanta Bioscience Ltd?

    Answer Field

    The 52 Week High and Low of Vanta Bioscience Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 31.33 and ₹ 14.71.

    What is 1 year return for Vanta Bioscience Ltd?

    Answer Field

    The 1 year returns on the stock has been -4.24%.

    What is the P/E Ratio of Vanta Bioscience Ltd Share?

    Answer Field

    As on Jul 06 2026 12:00 AM the price-to-earnings (PE) ratio for Vanta Bioscience Ltd share is 148.76.

    What is the PB ratio of Vanta Bioscience Ltd Share?

    Answer Field

    As on Jul 06 2026 12:00 AM, the price-to-book (PB) ratio for Vanta Bioscience Ltd share is 29.88.

    How to Buy Vanta Bioscience Ltd Share?

    Answer Field

    You can trade in Vanta Bioscience Ltd shares with Bajaj Broking by opening a demat account.

    How to Buy Vanta Bioscience Ltd Share on Bajaj Broking App?

    Answer Field

    To buy Vanta Bioscience Ltd shares on the Bajaj Broking app, follow these steps:

    • Login to the Bajaj Broking App

    • Click on the Search Icon

    • Search “Vanta Bioscience Ltd”

    • Click on the BUY icon

    • Place a buy order specifying the desired quantity of shares.

    • Click BUY again to complete the purchase

    No results found

    close-img
    Authorise with OTP
    Enter the 4-Digit OTP sent to
    edit
    OTP expires in 00:59
    banner-icon

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |